Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

siRNA drug safely halved LDL cholesterol in phase 3 ORION-11

Key clinical point: A new drug class safely cut LDL cholesterol with biannual injections in a phase 3 study.

Major finding: Four inclisiran injections administered over 15 months cut baseline LDL cholesterol levels by 50% throughout the study period.

Study details: ORION-11, a multicenter, randomized, phase 3 study with 1,617 patients.

Disclosures: ORION-11 was sponsored by the Medicines Company, which is developing inclisiran. Dr. Ray is a consultant to it and to several other companies.

Citation:

REPORTING FROM THE ESC CONGRESS 2019